Loading...
•
Dec 31, 2025
BeiGene Q4 2025 Earnings Report
BeOne Medicines reported strong fourth quarter 2025 results with significant revenue growth and a return to GAAP profitability.
Key Takeaways
BeOne Medicines achieved total Q4 revenue of $1.5 billion, a 33% increase year-over-year, driven by the global success of BRUKINSA which reached $1.1 billion in quarterly sales. The company transitioned to a GAAP net income of $66.5 million compared to a net loss in the prior year, supported by improved operating leverage and product margin expansion to 90.4%.
Global BRUKINSA revenues grew 38% year-over-year to $1.1 billion in Q4, establishing it as a leader in the BTK inhibitor class.
Achieved GAAP operating income of $185 million in Q4, a significant turnaround from a $79.4 million loss in the prior year period.
Free cash flow for the quarter reached $380 million, an increase of $397 million compared to Q4 2024.
Product gross margins improved to 90.4% on a GAAP basis, driven by favorable product mix and manufacturing efficiencies.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
BeOne Medicines expects total revenue for FY 2026 to be between $6.2 billion and $6.4 billion, driven by BRUKINSA's market leadership.
Positive Outlook
- Total revenue guidance of $6.2 billion to $6.4 billion.
- GAAP gross margin expected in the high-80% range.
- Non-GAAP operating income projected between $1.4 billion and $1.5 billion.
- Expected productivity improvements throughout 2026.
- Potential reversal of certain tax valuation allowances resulting in a material benefit.
Challenges Ahead
- GAAP operating expenses projected to rise to $4.7 - $4.9 billion.
- Other expense estimated range of $25 million to $50 million.
- Interest amortization from Royalty Pharma arrangement impacting expenses.
- Uncertainty regarding the timing and magnitude of tax allowance reversals.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...